TABLE 1.
Summary of NK‐, CIK‐, and iNKT‐cell‐based clinical trials for adoptive cellular therapy of cancer completed on or after 1 January 2010
| Approach/treatment | Disease | Patients (total) | Trial identifier |
|---|---|---|---|
| NK | |||
| Autologous NK cell transfer (+/− chemotherapy, IL‐2/−15, K562‐mb15‐41BBL, CTLs, and/or monoclonal antibodies) | Pediatric cancers, neuroblastoma, sarcoma, brain and solid tumors, HCC, MM, prostate cancer, glioblastoma, and B‐cell lymphoma | 139 | NCT01875601, NCT0114738, NCT01884688, NCT02481934, NCT01313897, NCT00891345, NCT01422850, NCT01588769, NCT02843061 |
| Allogeneic NK cell transfer (+/− chemotherapy, HSCT, IL‐2, and/or cryosurgery) | Advanced biliary tract cancer, liver metastases of colorectal or pancreatic cancers, lymphomas, leukemias, ovarian cancer, fallopian tube carcinoma and primary peritoneal cancer, breast cancer, NSCLC, neuroblastoma, and HCC | 207 | NCT03358849, NCT02845999, NCT01212341, NCT01853358, NCT01287104, NCT01105650, NCT01181258, NCT00303667, NCT00383994, NCT02843815, NCT02008929 |
| Haploidentical NK cell infusions (+/− chemotherapy, HSCT, IL‐2/IL‐15, 41BBL, CNDO‐109, genetic modification, KIR‐ligand mismatch, and/or monoclonal antibodies) | NSCLC, neuroblastoma, lymphoma, leukemia, MDS, myeloma, ovarian cancer, fallopian tube carcinoma, primary peritoneal cancer, MM, neuroblastoma, rhabdomyosarcoma, and melanoma | 526 | NCT03366064, NCT02130869, NCT00640796, NCT00697671, NCT00660166, NCT01947322, NCT02118285, NCT01385423, NCT01795378, NCT00995137, NCT00089453, NCT00823524, NCT00187096, NCT02074657, NCT02395822, NCT00877110, NCT01576692, NCT01386619, NCT00846833, NCT00526292, NCT01593670, NCT00402558, NCT01390402, NCT01520558 |
| NK cell line NK‐92 (+/− CAR) | Leukemia, lymphoma, MM, Hodgkin's disease, and solid tumors | 21 | NCT00990717, NCT00900809, NCT03027128 |
| Unspecified NK cell transfer + cryosurgery | Advanced kidney cancer, advanced breast cancer, liver cancer, and esophageal cancer | 200 | NCT02843607, NCT02844335, NCT02849015, NCT02843802, NCT02843581 |
| CIK | |||
| Autologous CIK cell transfer (+/− surgery, stem cell transplant or RFA) | HCC, hematological malignancies, CRCLM | 499 | NCT00769106, NCT01749865, NCT00477035, NCT00394381, NCT02419677 |
| Autologous DC‐CIK (+/− surgery, chemotherapy, or γδ T cells) | Pancreatic, liver, colorectal, prostatic, renal, lung, gastric, and breast cancer | 799 | NCT02406846, NCT02416635, NCT02450422, NCT02450435, NCT02450448, NCT02412384, NCT02450357, NCT02425735, NCT02418481, NCT02425748, NCT01781520, NCT01783951, NCT01232062, NCT01395056 |
| CIK cell agent following curative resection (PEIT, RFA, or surgery) | HCC | 230 | NCT00699816 |
| Allogeneic CIK cell transfer following allogeneic stem cell transplantation | MDS, MPD, and hematologic malignancies | 142 | NCT01392989, NCT01186809, NCT00460694 |
| iNKT | |||
| Autologous iNKT cells | Malignant melanoma | 9 | NCT00631072 |
Abbreviations: CIK; cytokine‐induced killer, CRCLM; colorectal cancer liver metastases, CTL; cytotoxic T lymphocyte, HCC; hepatocellular carcinoma, HSCT; hematopoietic stem cell transplantation, iNKT; invariant natural killer, IL; interleukin, KIR; killer cell immunoglobulin‐like receptors, MDS; myelodysplastic syndromes, MM; multiple myeloma, MPD; myeloproliferative disorders, NK; natural killer, NSCLC; non‐small cell lung cancer.